Published in JAMA · View the paper (DOI)
A clinical trial found that intensive cholesterol-lowering therapy reduced the risk of cardiovascular events by 31% in high-risk patients with diabetes. The treatment, evolocumab, lowered LDL-C levels by approximately 60%, and was well-tolerated.
Coverage from 2 institutions